• Cepton, in collaboration with ZKW Group GmbH, plans to showcase its Nova lidar headlamp integration into a ZKW heavy-duty truck headlamp at the IAA Transportation Conference (Sept. 20-25, 2022)
• Nova is an award-winning, miniature, wide field of view, near-range lidar sensor that provides high resolution 3D imaging in a compact form factor
• Nova integrates seamlessly around vehicles to provide 360-degree perception boosting blind spot detection, which is becoming a mandated vehicle safety feature

The success of autonomous vehicles (“AV”) and advanced driver assistance systems (“ADAS”) hinges on technologies that make 360-degree intelligent perception possible. Cepton (NASDAQ: CPTN), a Silicon Valley innovator of lidar-based solutions for the automotive (“ADAS/AV”) and smart technology spaces, is leading the way with Nova, an award-winning short-range lidar solution that’s lightweight, flexible, energy-efficient, and easy to integrate into passenger and commercial vehicles. CPTN recently announced the company’s collaboration with ZKW Group GmbH to demonstrate Nova at the upcoming IAA Transportation conference from September 20-25, 2022 (https://ibn.fm/rB5BJ). “We are excited to showcase our collaboration with ZKW at this year’s IAA event,” said Dr. Jun Pei, Cepton’s CEO and co-founder. “ZKW is a leading innovator of automotive lighting technologies and working with the ZKW team allows Cepton to demonstrate how our lidars are optimized for use in everyday vehicles.” Cepton’s exhibit will demonstrate how Nova helps eliminate blind spots and create a “safety cocoon” around the vehicle by combining high-resolution, superior field of view coverage in all directions. Nova’s super-compact form additionally features flexible options to integrate discretely in various locations around the vehicle to provide complete 360-degree perception that accurately detects objects from every direction, including pedestrians, bicycles, and low-proximity obstacles on the road surface. “Being able to be seamlessly integrated into locations like headlamps is a key factor of the outstanding scalability of Cepton lidar,” said Dr. Pei. “With that, we aim to bring lidar’s safety benefits to everyone on the road – drivers, passengers, and road users alike – while helping advance the future of autonomous mobility.” During the IAA Transportation conference exhibit, Nova will be integrated into a heavy-duty truck headlamp provided by ZKW. The headlamp integration solution features sensor protection and a cleaning mechanism that facilitates user maintenance. “For us as an innovative supplier of premium lighting systems, it is very important to engage with the right technologies,” said Dr. Wilhelm Steger, CEO of the ZKW Group. “That’s why we are constantly on the lookout for competent partners – like here in the field of lidar with Cepton.” Cepton’s patented lidar technology enables an optimal balance between performance, reliability, and cost efficiency. The company offers a comprehensive portfolio of lidar solutions, including lidar sensors for near to ultra-long-range applications, and intelligent perception solutions that can be applied to smart cities, smart spaces, and smart industrial applications. For more information, visit the company’s website at www.Cepton.com. NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

• Global cannabis brand-builder Flora Growth recently named a former Amazon financial executive as its new CFO
• Elshad Garayev will work with outgoing CFO Lee Leiderman to ensure a smooth transition of responsibility amid finalization of Flora’s mid-year financial filing with the SEC
• Flora Growth is headquartered in Canada with cultivation operations centered in Colombia, where recent government administrations have opened regulatory processes for exporting cannabis derivatives for the health and wellness markets
• The company continues to expand its operations internationally for sales in the UK and Europe generally, Australia, and throughout the Americas

Global cannabis brand-builder Flora Growth (NASDAQ: FLGC) has steadily built an aggressive international expansion of its Colombia-based cultivation operation during the past year and a half, launching exports to countries such as Mexico and Spain and opening doors to the United Kingdom and the United States. Flora Growth, which is headquartered in Ontario, Canada, and is establishing offices in the United States, also anticipates end user markets in Australia, various countries in Latin America, as well as in Europe and Asia. Flora Growth has recently named a former financial executive at Amazon, Boeing, BP, and RPK Capital, as the new chief financial officer, tasked with overseeing financial governance and effective cash position strategy as Flora moves towards quarterly financial reporting and solidifies its global growth. The company stated that Elshad Garayev will initially serve as vice president of finance while working with the outgoing CFO, Lee Leiderman, through a transition period culminating with Flora’s filing of its mid-year financial results with the Securities and Exchange Commission. Once that filing is completed, Garayev will take over as CFO on the following business day and Leiderman will move into an advisory role to help ensure a smooth continuation of operations, according to the July 11 announcement (https://ibn.fm/k94cm). “Mr. Garayev is a deeply talented and experienced individual, and I am thrilled to welcome him to the Flora team at this exciting time in the company’s evolution,” Chairman and CEO Luis Merchan stated in the announcement. “As Flora seeks to establish itself as a global leader in cannabis, adding someone of his caliber will further strengthen our position.” In addition, the company appointed JPMorgan Chase alum Brandon Konigsberg to their board of directors, and as a member of the audit and comp committees. “The addition of Mr. Konigsberg to our Board is further testament to our ongoing commitment to fiscal discipline and sound governance. He brings with him exceptional experience in the fields of finance and operations and will assist in helping our organization achieve rapid financial growth and maximize our shareholder value,” said Luis Merchan, Flora’s Chairman and CEO (https://ibn.fm/QokvH). “We are pleased to welcome Mr. Konigsberg as a valued member of our team and look forward to his contributions.” This year, the company has acquired 100 percent equity interests in Just Brands LLC and High Roller Private Label LLC as it has advanced its strategic position. The acquisitions brought the JustCBD brand into Flora’s stable (https://ibn.fm/Tvlz4), which is expected to in turn help the company expand its operational footprint in Europe and the United Kingdom through JustCBD’s 79 products authorized by the UK’s novel foods standards agency (https://ibn.fm/1cQO5). The company’s announcement states its JustCBD gummies and tinctures will begin selling on Amazon’s UK web portal this summer. Flora’s outdoor cannabis cultivation facilities in central Colombia grant it prime positioning for product growth in a fertile zone that is accessible to an experienced grower labor force. The company uses natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands, and life sciences divisions, which together form a design-led collective of plant-based wellness and lifestyle brands. For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• Medical company Odyssey Health has received approval from the Safety Review Committee to start Cohort II of its Phase I trial’s Multiday Ascending Dosing (“MAD”) stage
• The approval follows evidence that Odyssey’s PRV-002 concussion drug candidate was safe and well-tolerated, as seen in Cohort I of the MAD stage
• The pharmacokinetic analysis also supports the hypothesis that more drug is getting to the brain itself, backing the company’s use of its patent-pending breath-propelled intranasal drug administration device
• The company believes that the intranasal drug/delivery combination will be instrumental in the success of the PRV-002 drug candidate in planned Phase II/III trials

Odyssey Health (OTC: ODYY), a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs, has received approval from the Safety Review Committee to proceed with dosing and evaluation of Cohort II volunteers of the Multiday Ascending Dosing (“MAD”) stage of its ongoing Phase I clinical trial. Aimed at evaluating the safety and tolerability of the company’s novel drug candidate to treat concussion, PRV-002, the Phase I study involves healthy human volunteers who receive a dose of the drug. “After reviewing the data from MAD Cohort I, I have strong confidence that PRV-002 will continue to show safety during the final, high-dose MAD portion of the Phase I clinical trial. We have unanimously approved the start of MAD Cohort II,” Dallas Hack, MD, a member of the Safety Review Committee, told Neurology Live (https://ibn.fm/xftAb). In an August 10 news release, Odyssey announced the completion and safety findings from Cohort I, showing that PRV-002 was safe and well tolerated. The Cohort 1 of the MAD stage included eight healthy human subjects who received a low dose of intranasal PRV-002 for five consecutive days, followed by evaluations for abnormal responses. No severe adverse events were observed (https://ibn.fm/cXbkJ). Additionally, pharmacokinetic (“PK”) analysis of the data from the first Cohort provided new information that, Hack underlined, support the hypothesis that more drug is getting to the brain itself rather than the circulation. The PK analysis evidenced a direct linear relationship between drug dosing concentration and blood plasma levels. This means that the drug dosing concentration (amount of drug in the body) increased with a rise in blood plasma levels (concentration of the drug in the plasma). The PK analysis further showed that the blood levels of the intranasally administered active drug were substantially lower on average than what would ordinarily be expected with other routes of administration. Moreover, the evaluations did not reveal any appreciable accumulation of PRV-002 with consecutive day treatments, and the MAD did not alter blood samples. “The overall low levels of PRV-002 in the blood support the hypothesis that more drug is getting to the brain itself when administered with the intranasal device. If this turns out to be the case, not only can the targeted effects of the drug be more efficacious, but the drug will also likely have fewer potential side effects,” Hack continued. Hacks’ observation is consistent with separate comments by Odyssey Health CEO Michael Redmond and the company’s Head of Drug Development, Dr. Jacob VanLandingham. In an interview with the RedChip Companies published on YouTube (https://ibn.fm/COh15), Redmond said the breath-propelled intranasal device, which delivers a powderized drug through the upper chambers of the nasal cavity, enables the drug to cross the blood-brain barrier within five minutes, following which it “spreads out throughout the brain within 30 minutes and reverses the effects of a concussion.” On his part, Dr. VanLandingham believes intranasal brain-targeting will be instrumental in the success of PRV-002 should it be efficacious for concussed patients in the planned Phase II/III trials. The Phase II study is intended to evaluate the efficacy of PRV-002 in concussed patients. “So far, the intranasal drug/device combination has functioned nicely and has been well-tolerated in the clinical setting,” concluded Dr. VanLandingham. Odyssey is now looking to commence its Phase II clinical trial subject to the submission of the Phase I trial results and approval by, among other relevant regulatory bodies, the U.S. Food and Drug Administration (“FDA”). To that end, the company is currently scouting for clinical sites in collaboration with the U.S. military and developing the Phase II Investigator’s Brochure for the Phase II trial. For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• Todd Michaels, Correlate’s Founder, President, and CEO, appeared on the latest episode of the Bell2Bell Podcast, where he talked about the company’s background, its achievements so far, and what lies ahead
• Mr. Michaels highlighted the opportunity in solar power generation, acknowledging that by 2050, it should account for around 40% of the actual overall capacity of energy generation in North America
• He also cited the Inflation Reduction Act, which adds incentives that are expected to help drive a significant leap forward for Correlate
• Mr. Michaels also highlighted the steps made by the company so far in 2022, citing the uplisting on the Nasdaq and an agreement to acquire the leading efficiency and commercial solar business in the state of Hawaii
• He was keen to point out that the company’s future looks bright and even maintained potential revenue growth projections for the subsequent quarters of the 2022 financial year

While appearing on the latest episode Bell2Bell Podcast, Correlate Infrastructure Partners (OTCQB: CIPI) Founder, President, and Chief Executive Officer (“CEO”), Todd Michaels, expressed his optimism about the company’s future, while highlighting its achievements so far, and the opportunities that lay ahead (https://ibn.fm/D5ALR). Mr. Michaels was keen to share the company’s background, noting some of its critical commercial brands, mainly Solar Site Design and Correlate. He also highlighted the company’s plans to add technologies and companies to its portfolio in a move that looks to further scale the business through technology enablement and automation. Correlate has carved out a significant market in North America, offering solar energy solutions, energy storage, and even electric vehicle infrastructure. However, it acknowledges that tremendous opportunity lies in solar power generation, particularly given projections that by 2050, it will account for around 40% of the actual overall capacity of energy generation. “The solutions that we deploy through those programs and subsidiaries in different parts of the country are things like solar, [energy] storage, energy efficiency and electric vehicle infrastructure,” noted Mr. Michaels. “We do that today in residential, commercial and industrial [applications], along with the burgeoning space of community-scale projects,” he added. On August 15, 2022, the Inflation Reduction Act was signed, in what marks the country’s biggest climate package. The goal of the law is to cut domestic greenhouse emissions while also lowering prescription drug prices. From an emissions standpoint, this presents an opportunity for Correlate, mainly since it is already a key player in the clean energy space (https://ibn.fm/7hMnp). Mr. Michaels acknowledged the significance of this law, noting that “It has never been a better time for our business”, and indicating “We were on a great trajectory growing organically, but the incentives from the Inflation Reduction Act are going to be a major leap forward for our business,” he added. So far in 2022, Correlate has made significant moves to grow its brand equity and create value for its shareholders. In June, it applied for uplisting on the Nasdaq, and before that, it executed an agreement to acquire the leading efficiency and commercial solar business in Hawaii. Its projects are only getting bigger, its client pool is growing, and these, according to Mr. Michaels, are all setting the company up for further growth as time progresses. Throughout the podcast, Mr. Michaels expressed his optimism about the company’s performance while also attributing its current success to the team behind the scenes. More importantly, Mr. Michaels showed the company’s commitment to clean energy solutions and creating value for its shareholders, factors that have shaped its decision-making, and its trajectory so far. For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• CNS reported a decrease in losses from $3.8 million in Q2 2021 to $3.6 million in Q2 2022, as well as a drop in research and development expenses from $2.7 million to $2.2 million, with an increase in general and administrative expenses from $1.1 million to $1.3 million
• The company closed the quarter with $9.0 million in cash, and a working capital of approximately $10.3 million which, it is confident, will fund its operations into the 2023 calendar year
• CNS looks to continue site initiations across the U.S., Italy, France, Spain, and Switzerland, while also pushing for regulatory and ethics approvals specifically for Italy
• It maintains that its focus and priorities remain on advancing its clinical development program for Berubicin for the treatment of GBM

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology enterprise focusing on the development of novel treatments for brain tumors, just released its financial results for the second quarter (“Q2”) of the 2022 fiscal year ended June 30, 2022. Of note was a notable performance improvement, with losses dropping from $3.8 million during the same period in 2021 to $3.6 million in 2022. This improvement was mainly attributed to the decreases in the timing of drug development expenses (https://ibn.fm/TWnMh). Research and development expenses also dropped from $2.7 million in Q2 2021 to $2.2 million for Q2 2022. On the other hand, general and administrative expenses saw a bump to $1.3 million, up from $1.1 million during the same period in 2021. This was linked to overall growth in employee compensation, taxes, and legal and professional fees, all of which were offset by decreases in stock-based compensation and other expenses. CNS kicked off Q3 2022 with approximately $9 million in cash, and working capital of approximately $10.3 million, which, it is confident, will fund its operations into the 2023 calendar year. Currently, the company is exploring the full potential of its lead product candidate, Berubicin. Results from clinical studies over the last six months have proven fruitful, even as the company continues to work toward approval by the United States Food and Drug Administration (“FDA”). “Within the past 6 months alone, we have executed on a number of clinical and operational advancements including expanding our global presence with clinical approvals in Spain, France, and Switzerland to drive patient enrollment forward, as well as expanding eligibility for patients to participate in our potentially pivotal study of Berubicin for the treatment of Glioblastoma Multiforme (‘GBM’) with our recently amended protocol, which was approved by the FDA, Swissmedic, National Agency for the Safety of Medicine and Health Products (‘ANSM’) Competent Authority and Corresponding European ethics committees,” noted John Climaco, CNS’ Chief Executive Officer (“CEO”). Even with the achievements thus far, CNS remains committed to advancing its research even further, taking advantage of the previously granted Fast Track Designation for Berubicin by the FDA. In addition, the company has received Orphan Drug Designation from the FDA, providing seven years of marketing exclusivity upon approval of a New Drug Application (“NDA”). CNS is looking to continue site initiations across the United States, Italy, France, Spain, and Switzerland while pushing for regulatory and ethics approvals specifically for Italy. It also seeks to commence patient enrollment across its European clinical sites even as it works towards the interim analysis of the trial when 30-50% of the total expected patients have been on study for at least six months. This, its management argues, defines the company’s focus and commitment to creating value for its shareholders. “Our focus and priorities remain on advancing our clinical development program for Berubicin to ultimately bring a meaningful treatment to GBM patients, families and clinicians, who currently have extremely limited and often ineffective treatment options,” noted Mr. Climaco. CNS continues to advance the development of its lead product candidate and its overall drug technology portfolio. It is indicative of its commitment to offering a solution to patients dealing with GBM, their families, and clinicians at the forefront of offering the necessary treatment services to these patients. More importantly, it indicates the company’s commitment to creating shareholder value and living up to shareholder expectations. Its management is confident that a significant performance improvement is imminent with the framework laid down so far. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Martin Shen, FingerMotion’s CEO, noted the company’s shift in focus to pushing gross margins higher for the 2022 calendar year
• This has shaped the company’s initiatives that have seen the addition of the mobile device protection service for the Chinese market
• Since launching the service, FingerMotion has received $4 million in funding from Lind Global Fund II, LP, and is confident that this investment will yield the highest return, strengthen the company’s balance sheet, and enable it to experience transformational revenue growth over the next 12-24 months
• Mr. Shen has maintained that the current revenue is just “the tip of the iceberg,” as it banks on the relationships forged with key players in the Chinese market, in addition to benefiting from a first-mover advantage
• Recent developments by the company show its commitment to offering unique services to the market, creating shareholder value, its understanding of the Chinese market, and the competence of its management

Earlier in the year, Martin Shen, the Chief Executive Officer (“CEO”) of FingerMotion (NASDAQ: FNGR), an evolving technology company with a core competency in mobile payment and recharge platform solutions in China, noted that the company would shift its focus for the 2022 calendar year. In addition, he noted that its initiatives would push gross margins higher, mainly building on the momentum gained so far in terms of performance. “One of our key initiatives is to keep pushing gross margins higher, and we have been quite successful by optimizing our product offerings,” he noted (https://ibn.fm/e68dO). FingerMotion previously focused on four company offerings: telecommunications products and services, SMS and MMS services, big data insights, and Rich Communication Services (“RCS”). However, it recently sought to further diversify this list by venturing into China’s mobile device protection business. Since launching the service, FingerMotion has closed a funding agreement to the tune of $4 million with Lind Global Fund II, LP, an investment fund managed by The Lind Partners, a New York-based institutional fund manager. Mr. Shen is confident that this investment, channeled into the mobile device protection business, will yield the highest capital investment return within the shortest time, indicating that “the company’s highest priority initiative is the full-scale nationwide rollout of its mobile device protection business in China,” allowing the company to “experience transformational revenue growth over the next 12-24 months.” (https://ibn.fm/84oU3). FingerMotion has, since its inception, never shied away from exploring new territories and trying out new revenue-generating initiatives. Having started with facilitating online payments, the company is set on its goal to serve over a billion users in the Chinese market, eventually expanding its model to other regional markets. This recent move has shown the company’s commitment to creating shareholder value, its understanding of the Chinese market, and recognition of its potential to be a leader in this market and beyond. Mr. Shen has even expressed cautious optimism on the company’s performance, noting that the 37% revenue growth during the past year is nothing but sustainable, mainly due to the company’s recent additions, specifically the device protection program. “I think our revenue right now is really just the tip of the iceberg,” Mr. Shen noted (https://ibn.fm/tFtDE). FingerMotion also banks on the amount of data it has acquired over the years and the relationships it has forged with key players in the Chinese market. In addition, it benefits from a first-mover advantage in consumer data analysis and payment processing within China, factors that set the company apart from other players in the industry. Mr. Shen acknowledges that this is integral to pushing the company’s gross margins higher for the 2022 calendar year. Shareholders and customers can expect a lot from FingerMotion going forward, and for a good reason. The company has shown commitment to offering unique services in the market and creating an environment where shareholders draw value from every decision made. This speaks to its understanding of the intricacies of the Chinese market and the competence of Mr. Shen’s team, which has been primarily responsible for the company’s success thus far. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• President Biden has signed his signature climate change legislation into law, providing hundreds of billions of dollars to spearhead decarbonization efforts
• Homeowners are highly incentivized to switch to perform energy audits and switch efficient electric technologies, the exact area of focus of GeoSolar Technologies
• GeoSolar Technologies SmartGreen(TM) systems use geothermal and solar technologies that align with government incentives to maximize home efficiency

On August 16th, President Joe Biden signed the Inflation Reduction Act (“IRA”) into law, earmarking some $369 billion in funding for energy and climate projects with the goal or reaching a 40 percent reduction in carbon dioxide emissions by 2030 compared to 2005 levels. Amongst other things, the new law includes a host of incentives for consumers to transition to renewable energy, which is a benefit to companies like GeoSolar Technologies (“GST”) that specialize in packages focused on energy efficient homes. The aptly named Denver-based company uses geothermal systems to capitalize on the near constant temperature of the ground for heating and cooling and solar panels on the roof to harness power from the sun’s rays to generate a house’s electricity needs. In between the roof and the footings, GeoSolar provides all the necessary products in its SmartGreen(TM) program to maximize a home’s efficiency, including new insulation, floor loops, high volume heat/air pump, LED lighting, and air purification system, none of which utilize fossil fuels. SmartGreen(TM) is applicable in commercial and residential properties, whether existing (retrofit) or new construction. The upstart, which is raising capital via a Regulation A+ offering, has installed its home technology on multiple test homes in Colorado, scoring at the upper echelon of the industry-standard Home Energy Ratings System (“HERS”) index. The company claims that SmartGreen(TM) technology reduces or eliminates utility bills and cuts carbon emissions by 8 tons a year. GeoSolar’s quest to achieve carbon-free living by 2035 squares with President Biden’s signature legislation. IRA extends (or replaces) incentives and rebate programs and allocates capital for 950 million solar panels, 120,000 wind turbines, and 2,300 grid-scale battery plants. Homeowners can benefit to the tune of $14,000 in home energy rebates for installing electric appliances. Starting January 1, 2023, the Energy Efficient Home Improvement Credit replaces the Nonbusiness Energy Property credit. The new law provides a tax credit equal to 30 percent of the costs for all eligible home improvements made during 2023, including things such as electric panels, heat pumps, and energy audits, all things that GeoSolar provides. Further, consumers are goosed to buy an electric vehicle, via a $7,500 tax incentive for a new EV or $4,000 for a used one. Each SmartGreen(TM) system includes a new EV charging station installed in the garage and powered by the rooftop photovoltaic solar panels. According to an August brief from electrification nonprofit Rewiring America, the savings can add up to lifechanging money. The organization estimates that a household switching fossil fuel dependence to an electric heat pump, heat pump water heater, solar panels, and one electric vehicle would save $1,800 annually. Using the savings to further electrify the house will result in compounding savings, which Rewiring America says can grow into $140,000 after 25 years. When Biden opines on how IRA fights inflation and gives everyday people extra disposable income, this is part of the rationale. Electrek provides a comprehensive view on how IRA and electrification to cut our dependence on the gas and oil industry can help dull the effect of GDP-based recessions. It’s going to take leaders in the decarbonization movement to make this happen. For more information, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• McKinsey & Company predicts battery electric vehicles and plug-in hybrid electric vehicles will comprise over 55% of new vehicle production by 2030
• Hillcrest Energy is bringing to market novel inverter technology as EV manufacturers transition to next-generation technologies, including 800-volt platforms
• Hillcrest Energy has released white papers showing the value of its inverter tech to eliminate losses and reduce capacitor size and weight, while improving power, reliability, and product life

The last couple years have presented a spate of challenges to the electric vehicle (“EV”) industry. 2020-2022 has been marked by supply chain disruptions, spikes in wholesale costs, and rise in wsticker prices that earned the ire of some consumers despite government incentives supporting the transition away from fossil fuel-powered vehicles. A deeper dive reveals an industry in transition for the better, as new technology, such as next-gen inverters from Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F), improve efficiencies across the battery-powered spectrum. Spurred on by global mandates to curb emissions, the EV market is accelerating in the face of any obstacles. Pundits remain bullish on the future, including global management consulting firm McKinsey & Company predicting battery electric vehicles (“BEVs”) and plug-in hybrid electric vehicles (“PHEVs”) will comprise over 55% of new vehicle production by 2030 in North America, China, and Europe. If the European Union has anything to say about it, that estimate may be light considering the bloc recently upheld its ban of new internal combustion engine (“ICE”) vehicle sales after 2035. Hundreds of automakers are now focused on the EV space, leaving behind many conventional technologies in favor of those that make vehicles lighter, less expensive (in the long run) with greater range. Some are even experimenting with integrated solar body panels so the vehicle can harvest power non-stop. One trend is to ditch the 400-volt platform for an 800-volt system. 800-volt platforms require optimizations but are a value proposition by significantly improving efficiency while minimizing joule loss and weight (owing to less high voltage cabling requirements). Minimizing size is a popular theme in vehicle electrification, which squares with the products of Hillcrest as it develops a pipeline of transformative power conversion technologies and control system solutions for next-generation electric vehicles and electrical systems. Most recently, the British Columbia-based company has been highlighting a new soft-switching technology for improving power density through the reduction of capacitor and overall inverter size. Generally speaking, there are a bank of capacitors in an inverter for the purpose of allowing pulses of electrical current to happen at different times and frequencies. This action serves several purposes, including reducing the amount of peak-to-peak ripple voltage. Smaller capacitors mean smaller inverters, which translates to less weight without sacrificing performance. In fact, it can improve performance and lower costs. Industry-wide, extrapolating small changes in materials and battery capacity can translate to large reductions in supply chain demand. In August, Hillcrest released a technical white paper outlining the advantages of its novel Zero Voltage Switching inverter and how its soft-switching capabilities relate to capacitors within the power conversion system. The report details the benefits of operating electrical systems at higher switching frequencies as a means to substantially reduce capacitor size, and improve power and reliability, while extending component life. It followed a July report on how Hillcrest technology eliminates losses and improves motor efficiencies. Hillcrest says that it is on schedule to deliver commercial prototypes of its new inverter to interested parties, including multiple global tier 1 automotive suppliers and original equipment manufacturers (“OEMs”), by the fourth quarter. The company has overcome typical issues with developing new inverter technology, namely eliminating high-frequency ringing in the power modules. “Based on our ongoing conversations with potential customers, we believe our business model – largely based on a combination of unique, application-specific hardware and software designs and ongoing product royalties/fees – aligns perfectly with what the industry is looking for,” said Hillcrest CEO Don Currie in a statement. He added that the strategy is to retain ownership of its core intellectual property and de-risk via creating multiple revenue streams by choosing a select group of non-exclusive partners that could deploy the inverters throughout different markets and sectors. For more information, visit the company’s website at www.HillcrestEnergy.tech. NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF

• Lexaria, a global innovator of drug delivery platforms is looking to provide a FDA registered hypertension treatment with its patented DehydraTECH technology
• The company’s efforts are encapsulated in its DehydraTECH-CBD that has been shown to lower blood pressure as well as reduce arterial stiffness
• Although hypertension is a devastating condition that can cause not only life-threatening illnesses but also death, only about 53% of Americans with the condition have it under control
• A Harvard Health article notes that the remaining portion (47%) are not able to control the disease because they are discouraged by medications’ side effects
• Lexaria’s DehydraTECH-CBD may well be the solution such individuals seek, but for now, the company is following the regulatory pathway to eventual drug approval

Hypertension causes life-threatening conditions such as stroke, heart attacks, coronary artery disease, and heart failure. But even more concerning, the condition leads to death. In 2020, the U.S. Center for Disease Control (“CDC”) reported that high blood pressure claimed more than 670,000 lives in the U.S. (https://ibn.fm/TI3fx). Globally, hypertension claims an estimated 7.5 million lives annually, according to the World Health Organization (“WHO”) (https://ibn.fm/3yda2). Despite these devastating consequences and statistics, only about half (53%) of Americans living with high blood pressure have it under control, a problem that a Harvard Health article attributes to, among other common reasons, the fact that many stop taking their medication citing side effects (https://ibn.fm/ScKA6). As a result, scientists and researchers have continuously explored ways to increase the chances of success as regards having the condition under control. One such study, a clinical trial, employed “a new strategy where patients are started on a pill containing four medicines, each at a quarter of their usual doses. [The strategy] has been shown to be much more effective in getting blood pressure under control, compared to the common practice of monotherapy, where treatment commences with just one drug” (https://ibn.fm/CbeZQ). For researchers and scientists at Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, their quest takes a different approach that combines the effectiveness of the company’s proprietary DehydraTECH(TM) drug delivery technology and the emerging benefits of cannabidiol (“CBD”), one of which is the substance’s ability to slow down the heart rate and blood pressure, particularly in stressful situations (https://ibn.fm/uDCGb). In the latest tests, DehydraTECH-CBD has undergone human evaluations, yielding promising results. CBD lowers systolic blood pressure in isolation (https://ibn.fm/U9xBC). However, with the addition of DehydraTECH, its capability and performance are boosted even further (https://ibn.fm/FZDkU). This is chiefly because DehydraTECH increases CBD’s bioavailability, a term that refers to the percentage of a drug that enters the bloodstream and becomes available to the intended biological target. In its first human study, conducted in 2018 and involving 12 patients, Lexaria showed that DehydraTECH delivered 317% more CBD to the bloodstream 30 minutes after ingestion (https://ibn.fm/gNDcX). Since then, the company has undertaken a series of other human studies. 2021, in particular, saw the company complete three studies: HYPER-H21-1, HYPER-H21-2, and HYPER-H21-3. The first study evidenced a rapid and sustained decrease in blood pressure, particularly systolic pressure. The second study showed that DehydraTECH-CBD caused a 23% average reduction in overnight blood pressure in addition to reducing arterial stiffness. The third revealed that the substance caused a 41% overall attenuation in pulmonary artery systolic pressure among male participants. Its fourth study, HYPER-H21-4, is its most comprehensive yet. With dosing having been completed in late July, Lexaria announced that no serious adverse events were reported. “Demonstrating a noteworthy safety and tolerability profile relative to conventional anti-hypertensive medications is one of Lexaria’s major goals with this program, and avoiding serious adverse events at clinically efficacious doses will be a primary requirement to achieve eventual regulatory marketing authorization,” Lexaria CEO Chris Bunka said of the HYPER-H21-4 study (https://ibn.fm/BHKt1). The company looks to leverage the results of the fourth study to file an Investigational New Drug (“IND”) application seeking the U.S. Food and Drug Administration (“FDA”)’s approval to begin registered clinical testing at Phase I level or higher. The study, Lexaria observes, is designed to boost the company’s probability of success with the application. And as analysis contained in an August 11 press release shows, the commencement of Phase I (or even higher) studies, as and when it happens, could portend good tidings for the company’s investors. According to a valuation guide authored by Bay Bridge Bio, the potential valuation of a company increases as a company’s clinical trials move from Phase I through Phase III. Accordingly, Lexaria’s valuation may trend upward with time (https://ibn.fm/7kBHk). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• The UK has witnessed the fourth consecutive year of growth for independent artists and is on track for a fifth, exhibiting 28.9% penetration YTD in 2022
• Independent artists are not afforded the same support from the music industry with the option of maintaining control over their work
• Friendable’s Fan Pass Live artist platform is a 360-degree platform approach to music production, distribution, and marketing that keeps ownership in the artist’s hands

The music industry has traditionally been dominated by major record labels and their recording artists – but in 2021, the UK saw the fourth year of consecutive growth for independent artists, growing to just under 27% of the country’s music market share. This number was boosted by classic LP releases and 60 albums entering the Top 10 Official Albums Chart. The UK’s positive trend for indie artists continues into 2022 with 28.9% YTD, boosted by number one albums from The Wombats, Don Broco, Stereophonics, and rapper Central Cee (https://ibn.fm/YHGrw). Unlike mainstream record label artists, indie artists do not have the same support from the industry when producing, distributing, and marketing music – they must rely on third parties for help with this, which can result in a search for three or more separate entities to make these endeavors possible. One company is changing this dynamic for indie artists, making it possible for them to produce, distribute, and market their music on one platform. The platform – Fan Pass Live, the flagship offering from Friendable (OTC: FDBL), a mobile technology company and marketing company, accompanied by the company’s Artist Republik and FeaturedX offering, provides a 360-degree solution for indie artists who want to be in full control of their music production, distribution, and marketing efforts. The Fan Pass Live artist platform offering gives indie artists an advantage in today’s music industry, featuring:

• Music Distribution and Management
• Music Production Assistance
• Press Release and Instagram Promotion
• Digital Storefront Activation
• Artist Marketplace for Collaborations
• Merchandise, Logo, and Promotional Design Support
• Virtual Concert Booking and Ticketing Mobile Streaming Service
• Live Streaming Support
• Revenue from Fan Tips, Monthly Artist Contests, Merchandise, and Ticket Sales
• Access to Fan Data and Performance Analytics
• Monthly Artist Contests
• NFT Development and Metaverse Performances – coming soon

All of these options are available in one place – the first of its kind in the industry today, with affordable services provided by artists for artists. Through the Fan Pass Live artist platform, Friendable is making it possible for indie artists to be heard without the fees and contracts required by traditional record labels, with the support and stability of experts in the industry. The global independent artists and performing art companies’ market size is expected to continue growing, from $101.33 billion in 2021 to $163.14 billion in 2022, experiencing a CAGR of 61%. By 2026, the market is expected to reach $328.87 billion, growing at a CAGR of 19%. The growth is primarily due to companies rearranging operations and recovering from the impact of COVID-19, which had led to restrictions, including remote working, closures of commercial venues, and subsequent operational challenges (https://ibn.fm/gPKeD). With the advantage of offering indie artists various services on one localized platform, Friendable and the Fan Pass Live artist platform remove the guesswork artists go through when finding ways to get their music heard. The company is changing the dynamic of the music industry by providing a highly sought solution that enables indie artists to keep complete ownership of their music while also distributing and marketing it with the full support of the platform. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL